中国药物经济学2024，Vol.19Issue(8)：30-37,43,9.DOI:10.12010/j.issn.1673-5846.2024.08.005
麝香保心丸与通心络胶囊治疗冠状动脉粥样硬化性心脏病心绞痛的药物经济学评价
A Pharmacoeconomic Evaluation of Shexiang Baoxin Pills and Tongxinluo Capsule in the Treatment of Coronary Atherosclerotic Cardiopathy Angina Pectoris
王志军 1吕冬梅 1张桂娟 1高志成 1陈小菲 1李勇1
作者信息
- 1. 华北理工大学附属医院心内科,河北唐山 063000
- 折叠
摘要
Abstract
Objective To evaluate the cost-effectiveness of Shexiang Baoxin Pill and Tongxinluo capsule in the treatment of coronary atherosclerotic heart disease(CHD)angina pectoris.Methods Randomized controlled trials involving Shexiang Baoxin Pill versus Tongxinluo capsule in the treatment of CHD angina pectoris at home and abroad were searched.Quality evaluation was conducted after screening,and meta-analysis was performed using Stata 16.0 statistical software.In addition,the cost is calculated by referring to the drug price of various provinces and autonomous regions in China and combining with the drug quantity,and the cost-effectiveness ratio is further analyzed.Results Finally,11 literatures were included,involving 990 subjects.Compared with Tongxinluo capsule,the symptom effective rate of Shexiangbaoxin Pill was 9%(95%CI:-5%～21%,P=0.23),and the electrocardiogram effective rate was 12%(95%CI:1%～23%,P=0.03),indicating that the symptom effective rate and electrocardiogram effective rate of Shexiangbaoxin Pill were better than that of Tongxinluo capsule.Based on the national average situation,the incremental cost-effectiveness ratio was analyzed.Compared with Tongxinluo capsule,the incremental cost-effectiveness ratio of Shexiang Baoxin Pill in improving clinical symptoms was-285.26,indicating that Shexiang Baoxin Pill was more economical.The results of sensitivity analysis showed that compared with Tongxinluo capsule in most provinces and autonomous regions of China,the incremental cost-effectiveness ratio of Shexiang Baoxin Pill in improving clinical symptoms was negative,suggesting that Shexiang Baoxin Pill has a significant economic advantage.Compared with Tongxinluo capsule,the incremental cost-effectiveness ratio of Shexiang Baoxin Pill in improving ECG results was-570.53,indicating that Shexiang Baoxin Pill showed absolute economic advantage.The results of sensitivity analysis showed that the incremental cost-effectiveness ratio of Shexiang Baoxin Pill to Tongxinluo capsule in improving ECG results was negative in most provinces and autonomous regions of China,which also proved that Shexiang Baoxin Pill was more economical.Conclusion In the clinical treatment of CHD angina pectoris,Shexiang Baoxin Pill is superior to Tongxinluo capsule in improving clinical symptoms and electrocardiogram results,and in most provinces and autonomous regions of China,Shexiang Baoxin Pill has absolute economy compared with Tongxinluo capsule.关键词
麝香保心丸/通心络胶囊/冠状动脉粥样硬化性心脏病/心绞痛/药物经济学Key words
Shexiang Baoxin Pills/Tongxinluo capsule/Coronary atherosclerotic cardiopathy/Angina pectoris/Pharmacoeconomics分类
医药卫生引用本文复制引用
王志军,吕冬梅,张桂娟,高志成,陈小菲,李勇..麝香保心丸与通心络胶囊治疗冠状动脉粥样硬化性心脏病心绞痛的药物经济学评价[J].中国药物经济学,2024,19(8):30-37,43,9.
